配分額 *注記 |
4,680千円 (直接経費: 3,600千円、間接経費: 1,080千円)
2025年度: 2,860千円 (直接経費: 2,200千円、間接経費: 660千円)
2024年度: 1,820千円 (直接経費: 1,400千円、間接経費: 420千円)
|
研究開始時の研究の概要 |
Patient response rates to ICB/CAR-T therapies remain poor, due to lack of T-cell persistence.
In this research, I will identify T-cell priming conditions and tissue-derived signals for generating stem-like-TRM TILs, which can be further applied to generating CAR-T with greater longevity and memory.
|